Partner Headlines - AMGN

  1. Meet 5 Big Tech Stocks Expected To See Profits Surge

    IBD
  2. Amgen Just Crashed 50% In Premarket, Here's How It Looked

    Benzinga
  3. Druckenmiller Adds Healthcare Stocks to Portfolio

    GuruFocus
  4. Meet 5 Top Biotech Stocks Holding Up In Shaky Market

    IBD
  5. How Can Drugmakers Handle New Pricing Pressures?

    IBD
  6. Gilead Sciences Bucks Trend In Biotech Short Interest

    Benzinga
  7. 3 Biotech ETFs Rally On Merger News

    Benzinga
  8. New Trial Initiated Evaluating Amgen's Talimogene Laherparepvec ...

    Benzinga
  9. Hot Drugmakers Build More Labs, Grab Space In Boston

    IBD
  10. Large-Blend Funds Take The Lead For Year-To-Date Total Returns

    Benzinga
  11. A Look At 3 Overbought ETFs

    Benzinga
  12. Big CEOs Are Less Upbeat, But Plan To Hire More

    IBD
  13. Endonovo Therapeutics Receives Final Commissioned Report Recommendations ...

    GuruFocus
  14. Meet 5 Top Drug Stocks That Are Bolting Past Market

    IBD
  15. AMGEN

    IBD
  16. #PreMarket Primer: Tuesday, November 25: Violent Protests In ...

    Benzinga
  17. Dividend Aristocrats In Focus Part 45: AbbVie

    GuruFocus
  18. Amgen Announces Termination Of All Amgen-Sponsored Clinical Studies ...

    Benzinga
  19. #PreMarket Primer: Wednesday, November 19: Burst Of Cold Creates ...

    Benzinga
  20. Merck Drug Works: Vytorin Study Proves Successful

    IBD
  21. Events for the Week of Nov. 17-21, 2014

    Benzinga
  22. Amgen Shares Consolidating Ahead Of More Gains?

    Benzinga
  23. UPDATE: Deutsche Bank Reiterates On Amgen On Potential Of New ...

    Benzinga
  24. Amgen And AstraZeneca Announce Positive Results From Second Pivotal ...

    Benzinga
  25. Big Cap 20 Stuffed With Medical Names

    IBD
  26. Markets Mostly Lower As Americans Head To Vote, Oil Continues ...

    Benzinga
  27. AbbVie Beats Q3 Earnings Estimates, Raises Guidance

    IBD
  28. Ebola Vaccine Contenders

    Benzinga
  29. Stocks Trim Losses After Fed Report; Solarwinds Soars

    IBD
  30. UPDATE: Nomura Upgrades Amgen

    Benzinga
  31. Amgen resists pressure to split

    IBD
  32. Amgen: Stronger Drug Portfolio with Acquisition

    GuruFocus
  33. Amgen Refuses To Split, But Plans Hearten Investors

    IBD
  34. Amgen At All-Time High, Deutsche Bank Ups Price Target

    Benzinga
  35. Stocks Extend Gains As Alibaba, Tesla Rally

    IBD
  36. Stocks Launch In Climbing Mood; Amgen, Spirit Airlines Climbing

    IBD
  37. Amgen Rallies 3% After Announcing Growth And Capital Plans

    Benzinga
  38. Four Biotechs Lead Health Care Stocks In Big Cap 20

    IBD
  39. Amgen Q3 Earnings Beat Estimates; Guidance Mixed

    IBD
  40. Amgen Earnings Clear Views

    IBD
  41. Amgen Beats Q3 Earnings Estimates

    Benzinga
  42. Twitter Off, Amgen, Buffalo Wild Wings Up After Hours

    IBD
  43. Dow, Nasdaq Battle Near Flat Line; Energy Weighs On S&P 500

    IBD
  44. #PreMarket Primer: Monday, October 27: ECB Stress Tests In-Line ...

    Benzinga
  45. Earnings Scheduled For October 27, 2014

    Benzinga
  46. Keep an Eye on These 7 Stocks for October 27, 2014

    Benzinga
  47. Stocks Put End To Four-Week Slide

    IBD
  48. Fast Money Picks For October 23

    Benzinga
  49. Drug ETFs Attractive Buys On Pullback

    Benzinga
  50. Biotechs Show Fed Chief's Not Much Of A Stock Analyst

    IBD
  51. Daniel Loeb Comments on Amgen Inc

    GuruFocus
  52. Third Point Q3 2014 Investor Letter

    GuruFocus
  53. Markets In Rally Mode: S&P 500 And Nasdaq Surge As Dow Lags

    Benzinga
  54. Third Point's Notable Additions And Exit: Alibaba, eBay, Sony

    Benzinga
  55. Stocks To Watch For October 20, 2014

    Benzinga
  56. Celgene, Alexion Among 4 IBD 50 Medical s To Report

    IBD
  57. Regeneron's Eylea Tops Rivals

    IBD
  58. Amgen Announces Appointment Of R. Sanders Williams To Board Of ...

    Benzinga
  59. Regeneron Eye Drug Beats Rivals While Amgen Sues

    IBD
  60. Amgen Files Lawsuit Against Sanofi And Regeneron For Patent Infringement

    Benzinga
  61. Most Top Industry Groups Fall Harder Than Market

    IBD
  62. UPDATE: Amgen's BiTE Received FDA Priority Review Designation

    Benzinga
  63. Illumina Pads Gene Sequencing Lead With Pharma Deals

    IBD
  64. Some Old Stocks Still Have Young Legs

    IBD
  65. Amgen, Inc. Showing Strong Performance Despite Low Beta

    Benzinga
  66. Acorda To Buy Civitas, Gains Parkinson's Disease Drug

    IBD
  67. Most Big Cap 20 Stocks Near Entries, But Risks Exist

    IBD
  68. These 3 Biotech Stocks Just Hit New Highs

    Benzinga
  69. Amgen Submits Biologics License Application For Investigational ...

    Benzinga
  70. Amgen: Stronger Drug Portfolio with Acquisition

    GuruFocus
  71. Insider Buys at Halozyme Look to Improve Stock Outlook

    GuruFocus
  72. Amgen, Inc. Poised To Break Higher

    Benzinga
  73. UPDATE: Morgan Stanley Reiterates On Amgen, Inc. As Brodalumab ...

    Benzinga
  74. UPDATE: Morgan Stanley Reiterates On Amgen, Inc. Following Healthcare ...

    Benzinga
  75. Amgen, Inc. Showing More Upside Potential

    Benzinga
  76. Why Gilead Sciences, Inc. Is A Top Mutual Fund Holding

    Benzinga
  77. Novartis, Regeneron Cardio Results Pump Up Wall St.

    IBD
  78. Novartis, Regeneron Hit New Highs On Cardio Drugs

    IBD
  79. Amgen edges up on trial results

    IBD
  80. Stocks Hitting 52-Week Highs

    Benzinga
  81. Biotech ETFs Hitting New Highs On Takeover News (FBT, PBE, ITMN)

    Benzinga
  82. After Reaching All-Time Highs, How Can Gilead Sciences Continue ...

    GuruFocus
  83. HCP Boosts Of 29 Years Of Dividend Increases

    IBD
  84. The Tech Industry is Vanishing Before Our Eyes

    FoxBusiness
  85. Stocks End With Small Gains; Amgen Shrugs Off Drug Data

    IBD
  86. AMGEN

    IBD
  87. Top 4 Stocks In The Biotechnology Industry With The Highest Revenue

    Benzinga
  88. 4 Top-Rated Drugmakers Beat Q2 Earnings Estimates

    IBD
  89. Cancer 'Cocktail' Passes Test

    IBD
  90. Nasdaq Leads In Quiet Session; Priceline Nears Buy Point

    IBD
  91. Amgen Cancer Drug Kyprolis Succeeds In Trial

    IBD
  92. Morning Market Movers

    Benzinga
  93. Benzinga's Top #PreMarket Gainers

    Benzinga
  94. UPDATE: Amgen Announces Phase 3 ASPIRE Trial of Kyprolis Met ...

    Benzinga
  95. Stocks Mixed Despite Better-Than-Expected GDP

    Benzinga
  96. Amgen Price Target Raised by Various Analysts

    Benzinga
  97. Amgen Restructuring Plan, Q2 Earnings Send Stock Up

    IBD
  98. Quarterly “Beats”: Bah, Here Are Real Growers

    YCharts
  99. Amgen To Slash Workforce

    IBD
  100. Indexes End Lower As Russia Sanctions Hit Stocks

    IBD
Trading Center